Combination therapy with non-sulfonylurea insulin secretagouge (HR, 2.58; 95% CI, 1.16–5.75), and either monotherapy (HR, 2.27; 95% CI, 1.47–3.51) or combination therapy with insulin (HR, 3.79; 95% CI, 1.89–7.58) were found to be associated with the risk of AD (Table 3). The gene discussed is INS; the disease is Alzheimer disease.